MRSN — Mersana Therapeutics Share News
0.000.00%
Last trade - 00:00- $145.16m
- $88.77m
- $40.50m
Mersana slumps as FDA puts ovarian cancer studies on hold
US FDA puts Mersana Therapeutics' ovarian cancer drug studies on partial hold (updated)
Brief: Mersana Therapeutics Announces Partial Clinical Hold On Up-Next And Upgrade-A Clinical Trials
US FDA puts Mersana Therapeutics's ovarian cancer study on hold
Mersana Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Mersana Therapeutics Q1 collaboration revenue USD 7.802 million
Brief: Mersana Therapeutics Provides Business Update And Announces Q1 2023 Financial Results
Mersana Therapeutics Inc expected to post a loss of 44 cents a share - Earnings Preview
Mersana rises after peer Immunogen's ovarian cancer drug shows positive results
Brief: Mersana Therapeutics Inc- On March 23, Co Entered Into Fourth Amendment To Loan And Security Agreement
U.S. STOCKS ON THE MOVE-PagerDuty, Lipella Pharma, FedEx, First Republic
U.S. STOCKS ON THE MOVE-Occidental Petroleum, Telos, Designer Brands
U.S. STOCKS ON THE MOVE-Dollar General, First Republic Bank, Qualcomm
U.S. STOCKS ON THE MOVE-Adobe, Meta, Credit Suisse
JPM upgrades Mersana Therapeutics on upcoming cancer drug readout
U.S. STOCKS ON THE MOVE-Moderna, Genie Energy, Merck & Co
U.S. STOCKS ON THE MOVE-Tesla, Rivian, Phathom Pharmaceuticals
U.S. STOCKS ON THE MOVE-Eli Lilly, Mersana, Illumina
Mersana falls as FDA puts cancer drug trial on hold